Effects of α1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction

Journal of Urology

Volumn 172, Issue 2, 2004, Pages 758-762

  Gu, Baojun ^a,b   Reiter, Jerome P ^c   Schwinn, Debra A ^a   Smith, Michael P ^a   Korstanje, Cees ^e   Thor, Karl B ^a,b,d   Dolber, Paul C ^a,b  

^a Department of Surgery ^*  (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY   (United States)

^d Durham/Dynogen Pharmaceuticals Inc   (United States)

^e ASTELLAS PHARMA INC   (Japan)

Author keywords

Bladder; Bladder neck obstruction; Rats, Sprague Dawley; Receptors, adrenergic, alpha 1; Urination

Indexed keywords

5 METHYLURAPIDIL; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ALPHA 1D ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1D ADRENERGIC RECEPTOR; PHENYLEPHRINE; PROPYLENE GLYCOL; RECEPTOR SUBTYPE; TAMSULOSIN; UNCLASSIFIED DRUG; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER NECK STENOSIS; BLADDER TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MEAN ARTERIAL PRESSURE; MICTURITION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR VOLUME; URINARY FREQUENCY;

EID: 3142652574     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000131609.96301.e6     Document Type: Article

References (20)

1. Seaman, E. K., Jacobs, B. Z., Blaivas, J. G. and Kaplan, S. A.: Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment. J Urol, 152: 935, 1994
2. Michelotti, G. A., Price, D. T. and Schwinn, D. H.: Alpha-1 adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther, 88: 281, 2000
3. Djavan, B. and Marberger, M.: A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol, 36: 1, 1999
4. Guthrie, R. M. and Siegel, R. L.: A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther, 21: 1732, 1999
5. Kumar, V. I. and Dewan, S.: Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate. Int Urol Nephrol, 32: 67, 2000
6. Michel, M. C., Bressel, H. U., Mehlburger, L. and Goepel, M.: Tamsulosin: real life clinical experience in 19,365 patients. Eur Urol, suppl., 34: 37, 1998
7. Forray, C., Bard, J. A., Wetzel, J. M., Chiu, G., Shapiro, E., Tang, R. et al: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol, 45: 703, 1994
8. 1A-adrenoceptor antagonist, does not improve lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol, suppl., 167: 265, abstract 1044, 2002
9. 1-adrenergic receptor subtypes in human detrusor. J Urol, 160: 937, 1998
10. Smith, M. S., Shambra, U. B., Wilson, K. H., Page, S. O. and Schwinn, D. A.: alpha 1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha 1-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res, 63: 254, 1999
11. Hampel, C., Dolber, P. C., Smith, M. P., Savic, S. L., Thüroff, J. W., Thor, K. B. et al: Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol, 167: 1513, 2002
12. O'Connor, L. T., Jr., Vaughan, E. D., Jr. and Felsen, D.: In vivo cystometric evaluation of progressive bladder outlet obstruction in rats. J Urol, 158: 631, 1997
13. Sharp, T., Backus, L. I., Hjorth, S., Bramwell, S. R. and Grahame-Smith, D. G.: Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378. Eur J Pharmacol, 176: 331, 1990
14. Martin, D. J., Lluel, P., Guillot, E., Coste, A., Jammes, D. and Angel, I.: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther, 282: 228, 1997
15. Hieble, J. P., Kolpak, D. C., McCafferty, G. P., Ruffolo, R. R., Jr., Testa, R. and Leonardi, A.: Effects of alpha 1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity. Eur J Pharmacol, 373: 51, 1999
16. Richardson, C. D., Donatucci, C. F., Page, S. O., Wilson, K. H. and Schwinn, D. A.: Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate, 33: 55, 1997
17. Ford, A. P., Arredondo, N. F., Blue, D. R., Jr., Bonhaus, D. W., Jasper, J., Kava, M. S. et al: RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5- chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol, 49: 209, 1996
18. Akiyama, K., Hora, M., Tatemichi, S., Masuda, N., Nakamura, S., Yamagishi, R. et al: KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther, 291: 81, 1999
19. Piascik, M. T., Smith, M. S., Barron, K. W. and Soltis, E. E.: The regulation of regional hemodynamics by alpha-1 adrenoceptor subtypes in the conscious rat. J Pharmacol Exp Ther, 267: 1250, 1993
20. Rudner, X., Berkowitz, D. E., Booth, J. V., Funk, B. L., Cozart, K. L., D'Amico, E. B. et al: Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation, 100: 2336, 1999